Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. The company reported net income in the three month period ended March 31, 2013 of $0.2 million, as compared to a net loss of $2.0 million in the same period of 2012. The $2.2 million change from net loss in 2012 to net income in 2013 was primarily the result of a $5.4 million increase in revenue and a $0.1 million decrease in income tax expense, offset in part by a $2.7 million increase in operating expenses and a $0.6 million decrease in interest income. Basic and diluted net income per share were $0.01 for the three month period ended March 31, 2013, as compared to a basic and diluted net loss per share of $0.09 in the same period of 2012. Revenue increased to $12.5 million for the three months ended March 31, 2013 from $7.1 million in the same period of 2012, primarily as a result of the Company earning a commercial milestone from Daiichi Sankyo related to net sales of Inavir(R) in Japan and increased service revenue in 2013 due to the advancement of the Company's laninamivir octanoate program under the BARDA contract. Gain from operations was $30,000 against loss from operations of $2,630,000 a year ago period. Income before tax was $203,000 against loss before tax of $1,891,000 a year ago. For the six months, the company reported loss from operations of $15,672,000, loss before tax of $2,314,000 and net loss of $2,198,000 or $0.08 per diluted share on total revenue of $24,346,000 against loss from operations of $16,385,000, loss before tax of $13,793,000 and net loss of $13,289,000 or $0.59 per diluted share on total revenue of $13,329,000 a year ago period.

Biota Pharmaceuticals, Inc. announced changes to its Board of Directors, including the resignations of Dr. Raafat Fahim and Mr. Paul Bell, and the appointments of Ms. Anne M. VanLent and Mr. Michael R. Dougherty to fill those vacancies. Ms. VanLent will serve as Chair of the Audit Committee. Ms. VanLent joins Biota's Board with extensive experience in corporate advisory and financial services roles within life sciences. Ms. VanLent is currently the President of AMV Advisors. Previously, Ms. VanLent was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. Mr. Dougherty also brings to Biota significant corporate and operational life sciences experience, having served in key executive and director roles at several biopharmaceutical companies over his career. Most recently, Mr. Dougherty was Chief Executive Officer of Kalidex Pharmaceuticals.

Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2012. For the quarter, the company reported total revenue of $10,386,000 against $2,093,000 a year ago. Loss from operations were $7,825,000 against $8,416,000 a year ago. Income before tax was $4,823,000 against loss before tax of $7,575,000 a year ago. Net income was $4,829,000 against net loss of $7,055,000 a year ago. Basic and diluted income per share was $0.17 against basic and diluted loss per share of $0.31 a year ago. Revenue increased to $10.4 million for the three months ended December 31, 2012 from $2.1 million in the same period of 2011, primarily as a result of increased service revenue in 2012 due principally to the advancement of the laninamivir octanoate program under the BARDA contract and higher royalty revenue. For the year, the company reported total revenue of $11,850,000 against $6,239,000 a year ago. Loss from operations were $15,702,000 against $13,728,000 a year ago. Loss before tax was $2,517,000 against $11,902,000 a year ago. Net loss was $2,413,000 against $11,252,000 a year ago. Basic and diluted loss per share was $0.09 against $0.50 a year ago.